Bouligny IM, Maher KR, Grant S (2023) Mechanisms of myeloid leukemogenesis: current perspectives and therapeutic objectives. Blood Rev 57:100996

Article  CAS  PubMed  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345–1377

Article  PubMed  Google Scholar 

Nath R, Reddy V, Kapur A, Gebregergish S, Gurskyte L, Kulakova M et al (2019) Survival of relapsed/refractory acute myeloid leukemia (R/R AML) patients receiving stem cell transplantation (SCT). Biol Blood Marrow Transplant 25(3):S125

Article  Google Scholar 

Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M et al (2021) Outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center. Front Oncol 11:649209

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeWolf S, Tallman MS (2020) How I treat relapsed or refractory AML. Blood 136(9):1023–1032

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Dai Y, Pei X-Y, Grant S (2009) Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-x_L, and Mcl-1. Mol Cell Biol 29(23):6149–6169

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME et al (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102(2):652–658

Article  CAS  PubMed  Google Scholar 

Rosato RR, Almenara JA, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63(13):3637–3645

CAS  PubMed  Google Scholar 

Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R et al (2011) HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471(7336):74–79

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carrier F (2013) Chromatin modulation by histone deacetylase inhibitors: impact on cellular sensitivity to ionizing radiation. Mol Cell Pharmacol 5(1):51–59

CAS  PubMed  PubMed Central  Google Scholar 

Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102(3):673–678

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107(33):14639–14644

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492–2499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM et al (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55(10):2301–2304

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J et al (2012) Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 91(1):33–38

Article  CAS  PubMed  Google Scholar 

Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M et al (2015) A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs 33(2):371–379

Article  CAS  PubMed  Google Scholar 

Holkova B, Tombes MB, Shrader E, Cooke SS, Wan W, Sankala H et al (2011) Phase I trial of belinostat and bortezomib in patients with relapsed or refractory acute leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blast crisis. Blood 118(21):2598

Article  Google Scholar 

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458(7239):732–736

Article  CAS  PubMed  Google Scholar 

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115(18):3796–3800

Article  CAS  PubMed  Google Scholar 

Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L et al (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma. Blood 116(9):1515–1523

Article  CAS  PubMed  Google Scholar 

Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA et al (2013) Disrupting protein NEDDylation with MLN4924 Is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 19(13):3577–3590

Article  CAS  PubMed  Google Scholar 

Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D et al (2012) The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Can Res 72(13):3360–3371

Article  CAS  Google Scholar 

Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M et al (2015) Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol 169(4):534–543

Article  CAS  PubMed  Google Scholar 

Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S et al (2022) Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv 6(17):5132–5145

Article  PubMed  PubMed Central  Google Scholar 

Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99(25):16220–16225

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115(18):3796–3800

Article  CAS  PubMed  Google Scholar 

Glozak MA, Seto E (2009) Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1 *. J Biol Chem 284(17):11446–11453

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H et al (2013) Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 73(1):225–234

Article  CAS  PubMed  Google Scholar 

Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E et al (2010) Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 5(12):e14335

Article  CAS  PubMed  PubMed Central